Navigation Links
Watson Acquires Ascent Pharmahealth for AU$375 Million
Date:1/23/2012

cts this entity to manage the Ascent assets.

Under the terms of the agreement, Watson acquired Ascent Pharmahealth for AU$375 million (approximately $393 million US) in cash. Watson funded the transaction using cash-on-hand and borrowings from its revolving credit facility. The deal is expected to be immediately accretive to 2012 non-GAAP earnings. The transaction was signed and closed simultaneously.

Watson will discuss the acquisition in more detail during its 2012 Investor Meeting in New York City on January 24, 2012.  The meeting will begin at 8:00 a.m. Eastern Time and will be simultaneously webcast. The webcast will be available live to investors and the media on Watson's Web site or at the following link: http://www.videonewswire.com/event.asp?id=84459.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets. 

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

About AscentAscent Pharmahealth Ltd, previously part of Strides Arcolab Ltd, services markets in Australia, Singapore, Malaysia, Hong Kong, Vietnam, Thailand and other Asian countries with a range of generic pharmaceuticals, consumer skincare and over the-counter (OTC) medicines. Ascent has a regional manufacturing facility located in Singapore which manufactures prescription and OTC products in varied dosage forms for the Southeast Asia market. 
Ascent is one of Australia's leading suppliers of healthcare products to pharmacies a
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Watson to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
3. Watson Launches Generic LoSEASONIQUE(R)
4. Watson Launches Generic LIPITOR®
5. Watson to Present at the 2011 Piper Jaffray Health Care Conference
6. Watson Wins Kentucky Drug Pricing Litigation
7. Watson Confirms Exelon(R) Patent Challenge
8. Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA
9. Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
10. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
11. Watson to Present at the 2011 Annual Credit Suisse Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... May 15, 2012  Cardium Therapeutics (NYSE Amex: ... UK-based Angel Biomedical Limited, a subsidiary of Angel ... contract manufacturer, covering the manufacture of formulated collagen ... for marketing by the U.S. Food and Drug ...
... Novelos Therapeutics, Inc. (OTCQX: NVLT) , ... treatment and diagnosis of cancer, today announced that ... a U.S. multi-center Phase 1b dose-escalation trial of ... cancer patients with advanced solid tumors.  The first ...
Cached Medicine Technology:Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 2Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 3Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 4Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 5Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 6Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 2Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 3Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 4
(Date:4/20/2014)... PHILADELPHIA Researchers may have identified key genes linked ... pain than others, according to a study released today ... Neurology,s 66th Annual Meeting in Philadelphia, April 26 to ... significant because it provides an objective way to understand ... levels," said study author Tobore Onojjighofia, MD, MPH, with ...
(Date:4/18/2014)... have made a discovery that turns 160 years of ... material long known to be essential for the fast ... is not as ubiquitous as thought, according to a ... Harvard Stem Cell Institute (HSCI) and the University,s Department ... Professor Jeff Lichtman, of Harvard,s Department of Molecular and ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
Breaking Medicine News(10 mins):Health News:Low tolerance for pain? The reason may be in your genes 2Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2
... 6, 2010 (Philadelphia, PA) -- Src (short for sarcoma) ... in many cancer tumors, including medulloblastoma, the most common ... most promising targets for cancer therapy. A recent ... be effective in interfering with the cell cycle and ...
... Jens Bangsbo from the Department of Exercise and Sports ... intervention studies involving both men, women and children, who ... results from the studies are so remarkable that the ... are publishing a special edition issue entitled "Football ...
... wind up in ER during major U.S. holidays, researchers find, ... are injured during the holidays, it,s not too many chocolate ... damage, a new study shows. , Rather, it is the ... fall prey to, the researchers from Nationwide Children,s Hospital in ...
... ... Superfruit Companies , ... (Vocus) -- Tahitian Noni International (TNI) announced a new quarter of a million ... other product in the industry will measure up to Tahitian Noni Bioactive Beverages., , , ...
... ... Excellence in Financial Journalism Award from the New York State Society of Certified Public Accountants ... New York, NY ... CFO magazine , won an Excellence in Financial Journalism Award from the New York ...
... ... PeopleStreme Human Capital has announced a collaboration with SkillSoft ... its clients.,We are thrilled to collaborate with SkillSoft to provide SkillSoft’s ... is a clear leader in the provision of our technology enabled ...
Cached Medicine News:Health News:New pyrimidine compounds may lead to improved treatments for childhood brain cancer 2Health News:Scientists: Soccer improves health, fitness and social abilities 2Health News:Scientists: Soccer improves health, fitness and social abilities 3Health News:Scientists: Soccer improves health, fitness and social abilities 4Health News:Most Holiday Injuries to Kids Spurred by Everyday Mishaps 2Health News:Quarter of a Million Dollar Superfruit Challenge Announced 2Health News:CFO magazine Wins Excellence in Financial Journalism Award 2Health News:PeopleStreme Collaborates with SkillSoft for Learning Management Content 2
Children's Half Trial Frames...
Half Eye Trial Frame - Child...
Fitment fine fits handles SF1, SF2, SF3, SF4, SF13 and SF23. Sterile blade....
... blades offer the superior cutting advantages ... plus the exclusive Rib-Back design for ... brand producer offer the wide selection ... scalpels. Every blade is packaged in ...
Medicine Products: